Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Revathi Ananthakrishnan"'
Autor:
Shinichi Makita, Go Yamamoto, Dai Maruyama, Yuki Asano‐Mori, Daisuke Kaji, Revathi Ananthakrishnan, Ken Ogasawara, Lara Stepan, Claudia Schusterbauer, Nils Rettby, Jens Hasskarl, Koji Izutsu
Publikováno v:
Cancer Medicine, Vol 11, Iss 24, Pp 4889-4899 (2022)
Abstract The autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell product, lisocabtagene maraleucel (liso‐cel), is administered at equal target doses of CD8+ and CD4+ CAR+ T cells. This analysis assessed safety and efficacy of liso‐cel
Externí odkaz:
https://doaj.org/article/01555f722268410baca0cc3cbf1c71db
Publikováno v:
Contemporary Clinical Trials Communications, Vol 28, Iss , Pp 100943- (2022)
Bayesian Optimal Interval (BOIN) designs are a class of model-assisted dose-finding designs that can be used in oncology trials to determine the maximum tolerated dose (MTD) of a study drug based on safety or the optimal biological dose (OBD) based o
Externí odkaz:
https://doaj.org/article/4686e85293ac4c2497667bbefc621590
Publikováno v:
Contemporary Clinical Trials Communications, Vol 16, Iss , Pp - (2019)
Designs, such as the Eff-Tox, OBD (optimal biological dose), STEIN (simple efficacy toxicity interval), and TEPI (toxicity efficacy probability interval) designs, have been proposed to determine the optimal dose of a new oncology drug using both effi
Externí odkaz:
https://doaj.org/article/1ab33348da1c4c7dab00e2f1af6bace4
Publikováno v:
Contemporary Clinical Trials Communications, Vol 10, Iss , Pp 62-76 (2018)
With the emergence of immunotherapy and other novel therapies, the traditional assumption that the efficacy of the study drug increases monotonically with dose levels is not always true. Therefore, dose-finding methods evaluating only toxicity data m
Externí odkaz:
https://doaj.org/article/9848e8124510471fbbf8411d60a6b631
Autor:
Daniel J. DeAngelo, Wendy Stock, Anthony S. Stein, Andrei Shustov, Michaela Liedtke, Charles A. Schiffer, Erik Vandendries, Katherine Liau, Revathi Ananthakrishnan, Joseph Boni, A. Douglas Laird, Luke Fostvedt, Hagop M. Kantarjian, Anjali S. Advani
Publikováno v:
Blood Advances, Vol 1, Iss 15, Pp 1167-1180 (2017)
Abstract: This study evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of inotuzumab ozogamicin (InO) for CD22-positive relapsed/refractory acute lymphoblastic leukemia. In phase 1, patients received InO 1.2 (n = 3), 1.
Externí odkaz:
https://doaj.org/article/75e7d5b654074258b13162642cc5791e
Autor:
Revathi Ananthakrishnan, Stephanie Green, Mark Chang, Gheorghe Doros, Joseph Massaro, Michael LaValley
Publikováno v:
Contemporary Clinical Trials Communications, Vol 5, Iss C, Pp 34-48 (2017)
Dose finding Phase I oncology designs can be broadly categorized as rule based, such as the 3 + 3 and the accelerated titration designs, or model based, such as the CRM and Eff-Tox designs. This paper systematically reviews and compares through simul
Externí odkaz:
https://doaj.org/article/314820dbd9ad498fb0f13483d1cadbc8
Autor:
Revathi Ananthakrishnan, Philimon Gona
Publikováno v:
Open Access Journal of Clinical Trials, Vol 2010, Iss default, Pp 59-82 (2010)
Revathi Ananthakrishnan1, Philimon Gona21Cambridge, MA, USA; 2Boston University, Mathematics and Statistics Department, 111 Cummington St, Boston, MA-02215, USAAbstract: Clinical research and clinical trials of experimental drugs to treat human disea
Externí odkaz:
https://doaj.org/article/d106117ef62c408fbc867abcce1d0b11
Publikováno v:
International Journal of Biological Sciences, Vol 3, Iss 5, Pp 303-317 (2007)
Cell movement is a complex phenomenon primarily driven by the actin network beneath the cell membrane, and can be divided into three general components: protrusion of the leading edge of the cell, adhesion of the leading edge and deadhesion at the ce
Externí odkaz:
https://doaj.org/article/77bc3b4049254b00a39b4fdbb6ae9295
Autor:
Daisuke Minakata, Tadao Ishida, Kiyoshi Ando, Rikio Suzuki, Junji Tanaka, Shotaro Hagiwara, Revathi Ananthakrishnan, Shigeki Kuwayama, Mitsufumi Nishio, Yoshinobu Kanda, Kenshi Suzuki
Publikováno v:
International Journal of Hematology. 117:729-737
Background In the phase 2 KarMMa trial, patients with relapsed/refractory multiple myeloma (RRMM) achieved deep and durable responses with idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor (CAR) T cell t
Autor:
Madhav Dhodapkar, Melissa Alsina, Jesus Berdeja, Krina Patel, Ravi Vij, Xavier Leleu, Anna Truppel-Hartmann, Debashree Basudhar, Ethan Thompson, Xirong Zheng, Revathi Ananthakrishnan, Linda Favre-Kontula, Chiara Greggio, Lars Sternas, David Siegel
Publikováno v:
Blood. 140:7441-7443